NCT02654340 (TuScCom) is a clinical trial in Hypomelanotic Macules, sponsored by CENTOGENE GmbH Rostock.

Who is sponsoring NCT02654340?

NCT02654340 is sponsored by CENTOGENE GmbH Rostock.

What condition does NCT02654340 study?

NCT02654340 studies Hypomelanotic Macules, Facial Angiofibroma, Shagreen Patches, Ungual Fibromas, Cortical Dysplasia, Cardiac Rhabdomyoma, Lymphangioleiomyomatosis, Renal Angiomyolipoma, Subependymal Giant Cell Astrocytoma.

Is NCT02654340 still recruiting?

NCT02654340 is currently terminated. Last updated 10 February 2023.

Last reviewed 2023-02-10 · How we verify

NCT02654340: TuScCom

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)

Terminated Last updated 10 February 2023

What this trial tests

trial in Hypomelanotic Macules in 20 participants. Terminated before completion.

Timeline

1 August 2018

Primary endpoint
30 December 2022

30 December 2022

Quick facts

Lead sponsor	CENTOGENE GmbH Rostock
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 August 2018
Primary completion	30 December 2022
Estimated completion	30 December 2022
Sites	8 locations across Georgia, Pakistan, Sri Lanka, Romania, Lithuania, Albania, Egypt, India

Conditions studied

Hypomelanotic Macules — all drugs for Hypomelanotic Macules →
Facial Angiofibroma — all drugs for Facial Angiofibroma →
Shagreen Patches — all drugs for Shagreen Patches →
Ungual Fibromas — all drugs for Ungual Fibromas →

Sponsor

CENTOGENE GmbH Rostock

Who can join

Adults 2 to 50, any sex, with Hypomelanotic Macules or Facial Angiofibroma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH, Kademane K, Chai Soon Hou S, Jocelyn TXY, et al · · 2023 · cited 12× · PMID 37432030 · DOI 10.1002/14651858.cd011272.pub3

Verify or expand the search:

Other CENTOGENE GmbH Rostock trials

Trials by the same sponsor.

NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02654340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
Last refreshed: 10 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02654340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing